Panacos Appoints Scott McCallister, M.D., Chief Medical Officer
Wednesday November 1, 4:02 pm ET
<Getting closer to the results:-) Any guess if they are in Nov r Dec? >
WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC - News), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that Scott McCallister, M.D. has joined the Company as Chief Medical Officer. Dr. McCallister will be responsible for medical affairs and will spearhead the Company's Phase 3 development efforts for bevirimat. He will report to Graham Allaway, Ph.D., Panacos' President and COO.
Before joining Panacos, Dr. McCallister was Director of Virology, Global Medical Affairs for Bristol Myers Squibb Company (BMS). In this role, he was responsible for the global medical strategy of the anti-HIV protease inhibitor, atazanavir (REYATAZ), and coordinated the review and approval of other virology studies, both internal and external, at BMS. Prior to BMS, Dr. McCallister held positions of increasing responsibility at Boehringer Ingelheim Pharmaceuticals (BI), leading the international clinical development program and regulatory review process for its anti-HIV protease inhibitor, tipranivir (APTIVUS). At BI, Dr. McCallister coordinated the design, conduct, and analysis of more than 20 Phase I, II, and III tipranavir development trials, culminating in the FDA and EMEA approval of APTIVUS for the treatment of HIV infection in treatment-experienced patients. Dr. McCallister has also served as an Assistant Professor of Medicine at Rush Medical College, Medical Director of the Howard Brown Health Center, and Associate Chief of HIV Medicine at the Illinois Masonic Medical Center in Chicago, where he established a general HIV clinic, a drop-in sexually transmitted disease clinic, and a women's health clinic for indigent patients. Dr. McCallister completed his studies at St. George's University School of Medicine and the University of California, Los Angeles.
Graham Allaway commented, "We are pleased to welcome Scott to the Panacos team. The expertise and experience he has gained in bringing an HIV drug from Phase 2 through regulatory approval will be extremely valuable to Panacos. His background will be a great addition to the bevirimat development program and to our HIV pipeline programs. Scott will work closely with Dr. David Martin, our Senior Vice President of Drug Development, as bevirimat moves toward Phase 3 development." |
